These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21491667)

  • 41. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
    Franco CM; Popplewell LL; Horwitz SM
    Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Malignant lymphomas in the elderly.
    O'Reilly SE; Connors JM; Macpherson N; Klasa R; Hoskins P
    Clin Geriatr Med; 1997 May; 13(2):251-63. PubMed ID: 9115450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Difference in prognosis between T- and B-cell lymphomas: clinical study at Shikoku Cancer Center Hospital.
    Toki H; Okabe K; Kimura Y; Yumoto Y; Morita M; Ogushi I; Koike S; Takashima S; Sato G; Moriwaki S
    Jpn J Clin Oncol; 1986 Mar; 16(1):41-8. PubMed ID: 3486301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
    Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
    Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas.
    Majhail NS; Burns LJ
    Curr Hematol Rep; 2005 Jul; 4(4):252-9. PubMed ID: 16009039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
    Armitage JO
    Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular predictors of response in aggressive T-cell lymphomas.
    Foss FM
    Cancer J; 2011; 17(2):142-8. PubMed ID: 21427558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.
    O'Connor OA; Bhagat G; Ganapathi K; Pedersen MB; D'Amore F; Radeski D; Bates SE
    Clin Cancer Res; 2014 Oct; 20(20):5240-54. PubMed ID: 25320373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pralatrexate (Folotyn).
    Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
    Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PTCL therapies: a review of treatment and outline of novel therapies.
    Khan N; Cheson BD
    Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety considerations with the current treatments for peripheral T-cell lymphoma.
    Sethi T; Montanari F; Foss F
    Expert Opin Drug Saf; 2022 May; 21(5):653-660. PubMed ID: 35129014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiocentric T-cell lymphoma of the lung mimicking metastatic carcinoma. Case report.
    Karakuş S; Yalçin S; Güler N; Cöplü L; Ayhan A
    J Exp Clin Cancer Res; 1998 Sep; 17(3):371-3. PubMed ID: 9894778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel treatments for T-cell lymphoma.
    Cheah CY; Oki Y; Fanale MA
    Am Soc Clin Oncol Educ Book; 2015; ():e468-78. PubMed ID: 25993211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel therapeutic agents for T-cell lymphomas.
    Chan TS; Kwong YL; Tse E
    Discov Med; 2013 Aug; 16(86):27-35. PubMed ID: 23911229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
    Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
    Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drugs for aggressive B-cell and T-cell lymphomas.
    Murawski N; Pfreundschuh M
    Lancet Oncol; 2010 Nov; 11(11):1074-85. PubMed ID: 21051020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
    Foss FM
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel targeted therapies in peripheral T cell lymphoma.
    Jagadeesh D; Smith MR
    Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.